James N. Perry leads investment to accelerate development of a low-toxicity, high-precision cancer therapy
New York City, October 29, 2025
Cytometric Therapeutics, Inc., an oncology company applying functional cytometric profiling to drug discovery, today announced the closing of a $40 million funding round to initiate its first clinical trial and expand research operations in Huntington Beach, California.
“Our goal has always been to translate rigorous science into meaningful advances for patients,” said Paul Kanan, Chief Executive Officer. “This investment allows us to move our lead program into the clinic while strengthening the platform that enables our continuing pursuit of more effective and less toxic cancer therapies.”
The financing, led by James N. Perry, reflects strong confidence in Cytometric Therapeutics’ strategy to develop cancer therapies that combine high efficacy with low systemic toxicity. The proceeds will support the transition of the company’s lead therapeutic candidate into clinical testing and the enhancement of its laboratory infrastructure for advanced drug response modeling.
“We are entering an exciting phase for Cytometric Therapeutics,” added Dr. William R. Grace, Chief Medical Officer. “This funding enables us to launch our first clinical trial and to expand our research programs at our Huntington Beach laboratory, where our team continues to refine therapies.”
The upcoming clinical trial, expected to begin in early 2026, will evaluate safety, pharmacokinetics, and early efficacy of the company’s lead agent in patients with advanced solid tumors. The expanded laboratory will support translational research, biomarker discovery, and validation studies using patient-derived cancer specimens.
Cytometric Therapeutics unites decades of laboratory expertise with a mission to improve cancer treatment through functional precision medicine. The company’s work builds on a proprietary cytometric approach that tests living tumor samples directly against therapeutic agents, producing data that bridge laboratory insight and clinical decision-making.